How Medicinal Cannabis Prescribing Is Regulated in Australia

Australian regulatory information.

This page explains the legal and regulatory machinery behind medicinal-cannabis prescribing. Regulatory access is not clinical approval, and nothing here guarantees a prescription, treatment outcome or product supply.

Patients often ask whether medicinal cannabis is ‘legal’ or whether a doctor is ‘authorised’ to prescribe it. Those questions are understandable, but the Australian framework is more specific. Regulation determines how a therapeutic good can be accessed and supplied; clinical judgement determines whether prescribing is appropriate for a particular patient.

Most medicinal-cannabis products used in Australia are not included in the Australian Register of Therapeutic Goods (ARTG). The TGA therefore provides access mechanisms for unapproved therapeutic goods. The main medicinal-cannabis pathways are the Special Access Scheme (SAS) and the Authorised Prescriber (AP) pathway. A small number of medicinal-cannabis products are included in the ARTG and follow the usual requirements that apply to registered medicines.

For an official overview, see the TGA guide to accessing medicinal cannabis for a patient. This page is intentionally about regulation and prescribing authority. It does not attempt to replace DocTel’s prescription-assessment page or the broader Medicanna telehealth service.

Medicines included in the Australian Register of Therapeutic Goods (ARTG) have a regulatory status different from unapproved therapeutic goods. Most medicinal-cannabis products supplied through SAS or Authorised Prescriber pathways are not ARTG-registered, so an applicable access pathway is generally required in addition to the usual prescribing and dispensing requirements. Only a small number of medicinal-cannabis products are ARTG-registered. The evidence supporting individual unapproved products varies, and TGA access through SAS or Authorised Prescriber arrangements should not be confused with ARTG registration.

Rather than leaving patients with no lawful access while that evidence base matures, Australia uses separate access mechanisms — chiefly the Special Access Scheme and the Authorised Prescriber pathway — that let a registered practitioner access an unapproved product for a specific patient, or a defined class of patients, under conditions set by the TGA. These are established regulatory access mechanisms, but they do not mean the TGA has assessed an unapproved product for quality, safety and efficacy in the same way as an ARTG-registered medicine.

The practical consequence for a patient is that ‘unapproved’ does not mean ‘illegitimate’ — but it does mean the product has not been evaluated by the TGA to the same standard as a fully registered medicine, which is exactly why the practitioner’s own clinical judgement carries extra weight in this context.

Both pathways can support lawful access to an unapproved medicinal-cannabis product, but they serve different prescribing situations.

Which route applies depends on the practitioner, product and patient circumstances. The TGA explains the available medicinal-cannabis access pathways and the supporting SAS and AP guidance.

The Special Access Scheme provides pathways for registered health practitioners to access unapproved therapeutic goods for individual patients. The category and process depend on the patient’s circumstances, the practitioner type and whether the product fits an established pathway.

For medicinal cannabis, SAS Category B is a commonly used application pathway when the relevant eligibility requirements are met. Under SAS Category B, an eligible practitioner applies for approval to access an unapproved medicinal-cannabis product for an individual patient. Other SAS categories have different eligibility and notification requirements.

The TGA provides specific guidance for SAS individual-patient applications. From a patient perspective, SAS access is not a self-application process. The clinical practitioner is responsible for the relevant application or notification and for determining whether the treatment is appropriate. A patient cannot obtain TGA approval independently and then require a doctor to prescribe.

• The patient first needs a clinical assessment.
• The practitioner decides whether an unapproved medicinal-cannabis product is justified.
• The relevant SAS requirements are completed by the practitioner when that pathway applies.
• A lawful prescription and pharmacy supply process still remain necessary after regulatory access requirements are met.

The TGA describes the Authorised Prescriber pathway and its reporting requirements. The Authorised Prescriber pathway allows an eligible medical practitioner to prescribe specified unapproved therapeutic goods to a class of patients with a particular condition without seeking a separate SAS approval for every individual patient covered by the authorisation.

Authorised Prescriber status does not mean a doctor can prescribe indiscriminately. The practitioner must remain within the scope of the authorisation and professional obligations, assess each patient clinically and maintain the required records and reporting.

A worked example: a practitioner holding Authorised Prescriber status for a defined condition does not mean every patient who books a consultation with that practitioner should receive a medicinal-cannabis prescription. The authorisation describes what the practitioner is permitted to do within a defined class of patients — it does not describe an outcome that is owed to any individual patient who happens to consult them. Each patient still needs their own clinical assessment against the same standard that would apply under any other pathway.

For patients, the practical question is whether the practitioner has an appropriate lawful pathway and whether treatment is clinically justified.

A TGA pathway does not guarantee that medicinal cannabis is suitable for an individual patient, does not prove that an unapproved product will be effective, and does not remove the practitioner’s professional obligations. For the patient-safety implications beside these regulatory controls, see DocTel’s medicinal-cannabis safety and quality standards guide.

• Regulatory access is not a clinical endorsement.
• Authorisation is not automatic prescribing.
• A lawful prescription does not guarantee immediate pharmacy stock.

A clinician prescribing medicinal cannabis remains subject to the same fundamental professional duties that apply to other areas of medical practice: adequate assessment, informed consent, appropriate documentation, consideration of alternatives, safe prescribing and follow-up.

The presence of a TGA pathway does not reduce the need to review other medicines, mental-health history, pregnancy status, substance-use risk, impairment risk or the possibility that another diagnosis or treatment should be considered first.

In practice, the doctor may decide not to prescribe, may request further records, may recommend face-to-face assessment, or may suggest another treatment pathway. Those outcomes are compatible with a properly regulated service — an Authorised Prescriber declining to prescribe for a particular patient is not a failure of the pathway, it is the pathway working as intended.

• Document the clinical rationale for treatment decisions.
• Consider clinically appropriate ARTG-listed options before accessing an unapproved good where relevant.
• Provide information about risks, uncertainty and monitoring.
• Prescribe within professional scope and any applicable state or territory requirements.

Australia has a national therapeutic-goods framework, but controlled-medicine and prescribing requirements can also involve state and territory law. The exact administrative requirements can depend on the medicine, the patient and the jurisdiction.

Conceptually, the two layers answer different questions. The federal TGA framework governs whether a product can lawfully be accessed and supplied at all — the SAS and AP pathways described above. State and territory law can separately govern how a controlled medicine is prescribed, recorded and monitored within that state, and can include additional practitioner obligations on top of the federal ones, not instead of them. A practitioner operating a telehealth service across Australia needs both layers to be satisfied for each patient, not just one.

That is one reason generic online claims such as ‘approved Australia-wide’ can be misleading. A telehealth service can operate nationally while individual prescribing decisions still need to comply with the rules that apply to the practitioner and patient in their specific state or territory.

Patients do not need to become regulatory experts. They do need a practitioner who understands the relevant framework and can explain the clinical pathway in plain language.

Regulatory access, prescribing and dispensing are connected but distinct. A TGA access pathway may permit supply of an unapproved therapeutic good, but the clinician must still prescribe lawfully and the pharmacy must dispense in accordance with applicable requirements. DocTel Medicanna currently uses private prescriptions for medicinal cannabis rather than electronic prescriptions (eScripts).

Availability can vary by pharmacy, product category, stock and jurisdiction. A prescription does not create a guarantee that a particular product is immediately available. Patients should follow the pharmacy and practitioner instructions if a substitution, supply delay or clarification is required.

DocTel does not treat regulatory approval as a product reservation or an automatic dispensing outcome. For the detailed pharmacy and dispensing pathway itself, see DocTel’s prescription assessment page.

A legitimate telehealth pathway should make clear that the consultation is an assessment, not an automated approval process. The doctor should be able to decline prescribing, request more information or recommend another form of care.

The service should also distinguish clinical fees from medication and pharmacy costs. A consultation fee pays for a clinical assessment, not a guaranteed prescription or medicine. Patients comparing providers can use DocTel’s medical cannabis cost and clinic pricing guide to understand those cost components separately. The service should also explain that a prescription is only issued when appropriate and avoid presenting unapproved medicinal-cannabis products as ordinary consumer goods.

Patients who are unsure whether the pathway may be suitable can use DocTel’s Medicanna eligibility check before booking.

• Australian-registered practitioner involvement.
• Clinical history and current medicines reviewed.
• No guaranteed prescription or guaranteed product.
• Clear follow-up and safety expectations.
• Lawful pharmacy dispensing rather than direct consumer-product sales.

Medicinal cannabis has a lawful medical pathway in Australia, but the phrase ‘legal in Australia’ can hide several different questions. A product may be lawfully supplied only through a particular therapeutic-goods pathway. A practitioner must be entitled to prescribe within the applicable framework. A pharmacy must dispense lawfully. The patient must then use and possess the medicine in accordance with the prescription and the law.

Those layers are why a blanket statement such as ‘cannabis is legal’ is not a useful description of medicinal access. The lawful status of recreational possession, driving and prescribed therapeutic use are separate matters.

Patients should therefore rely on the instructions attached to their prescription and obtain jurisdiction-specific advice where driving, travel, workplace obligations or controlled-medicine rules are relevant. DocTel’s safety and standards guide covers the driving and impairment question from a patient-safety angle.

Regulated prescribing also creates documentation obligations. The practitioner needs a clinical record that supports the treatment decision, while particular access pathways can involve TGA notifications, applications or reporting. Authorised Prescribers also have reporting responsibilities attached to their authorisation; the TGA provides online-system and six-monthly reporting guidance.

This administrative layer is not visible to most patients, but it matters because it distinguishes a medical service from an unstructured product-sales model. Good documentation also supports continuity of care when another practitioner or pharmacist needs to understand what has been prescribed and why.

Patients can help by providing accurate information and by keeping their own prescription information, pharmacy labels and treatment instructions available for follow-up — incomplete histories or inconsistent information can delay a decision because the practitioner may need to verify facts before prescribing. This matters even more if a patient later changes pharmacy or treating practitioner, since accurate records help the new provider understand what has previously been prescribed and monitored.

If you are considering medicinal cannabis, DocTel Medicanna provides a telehealth assessment pathway. The consultation is a clinical assessment and does not guarantee a prescription or a particular medicine.